인자인케어센터

Loading...

Home > 게시판 > 갤러리

2020년 11월 김장 만들기 프로그램

2020-12-16

2021년 2월 생신잔치 프로그램

2020년 10월 인자인장터프로그램

작성자				비밀번호


, WilliamSEede (2026-03-31)
Zoya Demidenko: Researcher in Tumor Biology Zoya Demidenko is a prominent investigator affiliated with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she conducted research at the National Institutes of Health and New York Medical College, building a robust background in life science research. Demidenko's academic output encompasses several critical fields, including the PI3K/AKT/mTOR signaling cascade, cellular cycle regulation, cell senescence, and tumor biology. To date, she has written over 46 scientific papers, which have garnered over 4,100 citations a reflection to the influence of her work. One of her most significant achievements lies in elucidating the pathways of cell aging. Her work demonstrated that when the cell cycle is blocked but cellular expansion continues, cells experience senescence. Importantly, Zoya Demidenko established that this transition is controlled with drugs using compounds such as mTOR inhibitors. Zoya Demidenko has additionally added greatly to tumor management investigation, particularly in the area of cyclotherapy a method aimed at safeguarding normal tissue from cytotoxic treatment whilst leaving cancer cells vulnerable. This approach offers significant promise for diminishing the adverse effects of oncological therapy. Throughout her career, Demidenko has worked with prominent scientists worldwide, including Dr. Mikhail Blagosklonny. Her publications appears in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. <>1.03.2026 11:21] Папа: Possessing an h-index of 33, Zoya Demidenko is recognized as a widely cited contributor in contemporary biomedical research, with her discoveries go on to influence our comprehension of how biological cells grow old, respond to therapy, and how cancer may be more successfully combated. https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPALLO20ENTERPRISE2C20LLC&SearchNameOrder=RAPAN20P050001591430&ListNameOrder=RAPAMULTISERVICES20L220000371890&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord


, WilliamSEede (2026-03-31)
Zoya Demidenko: Researcher in Tumor Science Zoya Demidenko is a recognized researcher associated with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she worked at the National Institutes of Health and New York Medical College, establishing a robust foundation in biomedical study. Demidenko's academic contributions encompasses multiple pivotal domains, encompassing the PI3K/AKT/mTOR molecular pathway, cellular cycle control, biological aging, and tumor science. Currently, she has co-authored over 46 peer-reviewed publications, which have received over 4,100 citations a indicator to the influence of her work. Among her most notable contributions concerns understanding the mechanisms of cell aging. Her studies demonstrated that when the cell cycle is arrested yet cellular growth continues, cells undergo senescence. Importantly, Zoya Demidenko established that this process can be pharmacologically suppressed using substances such as mTOR inhibitors. Zoya Demidenko has additionally contributed considerably to tumor management investigation, notably in the domain of cyclotherapy a method intended to protecting non-cancerous tissue from chemotherapy whilst leaving tumor cells exposed. This approach offers significant promise for diminishing the side effects of cancer treatment. Throughout her career, Demidenko has worked with prominent researchers internationally, including Dr. Mikhail Blagosklonny. Her work can be found in top-tier publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. <>1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko stands as a influential voice in modern biomedical research, with her discoveries keep to guide our comprehension of how cells grow old, resist treatment, and the ways in which cancer may be better targeted. https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/


, WilliamSEede (2026-03-31)
Zoya Demidenko: Scientist in Oncology Studies Zoya Demidenko is a distinguished scientist associated with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she worked at the NIH and New York Medical College, establishing a solid base in life science study. Demidenko's scientific contributions covers a number of critical areas, among them the PI3K/AKT/mTOR signaling pathway, cell cycle regulation, cell senescence, and tumor science. To date, she has authored more than 46 academic articles, which have accumulated over 4,100 citations a testament to the influence of her work. One of her key discoveries lies in elucidating the processes of biological cell aging. Her studies revealed that when the cell cycle is halted yet cellular expansion persists, cells experience senescence. Importantly, Zoya Demidenko demonstrated that this shift is inhibited by medication using agents such as mTOR inhibitors. Zoya Demidenko has also added greatly to oncological therapy investigation, particularly in the field of cyclotherapy a approach aimed at safeguarding healthy tissue from chemotherapy while leaving cancer cells exposed. This approach carries considerable potential for diminishing the adverse effects of oncological therapy. Across her career, Demidenko has worked with prominent researchers worldwide, such as Dr. Mikhail Blagosklonny. Her research can be found in leading periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. <>1.03.2026 11:21] Папа: Holding an h-index of 33, Zoya Demidenko stands as a highly impactful contributor in modern cancer science, with her findings continue to shape our comprehension of the way biological cells grow old, interact with therapy, and the ways in which cancer might be more effectively combated. https://www.sciencedirect.com/science/article/abs/pii/037811199400784P


, WilliamSEede (2026-03-31)
Zoya Demidenko: Scholar in Tumor Studies Zoya Demidenko is a recognized scientist affiliated with the Unit of Cell Stress Biology at Roswell Park Oncology Institute in Buffalo, New York. Before that, she worked at the NIH and New York Medical College, developing a strong background in clinical study. Demidenko's scholarly output encompasses multiple critical fields, among them the PI3K/AKT/mTOR signaling cascade, cell cycle control, cell senescence, and tumor biology. To date, she has authored over 46 peer-reviewed papers, which have garnered over 4,100 citations a testament to the significance of her research. Among her most significant achievements lies in understanding the processes of biological cell aging. Her studies demonstrated that when the cellular division cycle is halted while cellular growth continues, cells enter senescence. Crucially, Zoya Demidenko showed that this process can be inhibited by medication using agents such as mTOR inhibitors. Zoya Demidenko has additionally added greatly to oncological therapy research, particularly in the field of cyclotherapy a approach aimed at protecting normal cells from chemotherapy while leaving tumor cells exposed. This method holds major promise for reducing the adverse effects of cancer treatment. Across her career, Demidenko has worked with leading investigators worldwide, among them Dr. Mikhail Blagosklonny. Her publications can be found in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. <>1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko is recognized as a highly impactful voice in modern biomedical science, with her results continue to shape our knowledge of the way cells grow old, interact with therapy, and how cancer might be better treated. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026126


, WilliamSEede (2026-03-31)
Zoya Demidenko: Scientist in Oncology Science Zoya Demidenko is a distinguished researcher associated with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she conducted research at the National Institutes of Health and New York Medical College, building a robust background in clinical research. Demidenko's scholarly contributions encompasses a number of pivotal fields, encompassing the PI3K/AKT/mTOR signaling cascade, cellular cycle control, cellular aging, and malignancy biology. Currently, she has written over 46 peer-reviewed papers, which have received more than 4,100 references a indicator to the influence of her research. One of her key contributions involves elucidating the mechanisms of cellular senescence. Her studies demonstrated that when the cell cycle is halted but cellular growth persists, cells enter senescence. Significantly, Zoya Demidenko showed that this shift can be controlled with drugs using substances such as mTOR inhibitors. Zoya Demidenko has also brought greatly to oncological therapy investigation, especially in the field of cyclotherapy a strategy intended to safeguarding healthy tissue from cytotoxic treatment while leaving malignant cells exposed. This method holds major hope for diminishing the side effects of oncological therapy. Throughout her career, Demidenko has worked with top scientists worldwide, among them Dr. Mikhail Blagosklonny. Her research is published in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. <>1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko stands as a widely cited contributor in modern biomedical science, whose findings go on to guide our knowledge of the way cells age, respond to therapy, and how cancer might be better treated. https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/

21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 |